This large multicenter real-world study of nearly 2,000 patients with drug-resistant focal epilepsy found cenobamate significantly more effective than brivaracetam, lacosamide, and perampanel for seizure reduction and freedom. Despite higher adverse effect rates, cenobamate showed superior treatment retention, providing practical guidance for ASM selection in refractory cases. Read more 22 Feb 2026 - less than 1 minute read
Large French registry study of 10,499 MS patients found that high-efficacy therapies (HET) do not meaningfully prevent progression independent of relapse and MRI activity (PIRMA) compared to moderate-efficacy therapies, despite better control of inflammatory activity. This challenges the assumption that more potent anti-inflammatory treatments will prevent all forms of disability progression in MS. Read more 21 Feb 2026 - less than 1 minute read
Large retrospective cohort study of 329,000 adults ≥65 years found that two-dose recombinant zoster vaccine (RZV) was associated with a 51% reduction in dementia risk over follow-up. The association remained significant (27% risk reduction) even after controlling for healthy vaccinee bias using Tdap vaccination as a comparator. Read more 21 Feb 2026 - less than 1 minute read
There is a lot of movement in the ALS space. Some recent advances include insight into the pathomechanism of one genetic variant and reports of the first successful treatment with no evidence of disease progression of another genetic variant. Read more 21 Feb 2026 - less than 1 minute read
Histopathological analysis of CNS tissues reveals distinct complement deposition patterns in NMOSD, MOGAD, and MS that reflect their different pathogenic mechanisms. Most importantly, MOGAD shows two distinct pathological subtypes based on complement activation intensity, with more intense C9neo deposition associated with higher mortality. Read more 17 Feb 2026 - less than 1 minute read